This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.
Supplementary Methods
External validation data (1) -The INTERMAP study investigates dietary and other factors associated with blood pressure 1 (BP). INTERMAP surveyed a total of 4,680 men and women aged 40-59 from 17 population samples in four countries (People's Republic of China, Japan, United Kingdom, and United States) at two timepoints ('visits'). Dietary intake data were collected at each visit from 24-hour recalls conducted by trained interviewers 2 . In this study, first visit data from the two U.K. population samples (n=499) were used to study the extrapolation of results from the controlled clinical trial data. The Dietary Approaches to Stop Hypertension (DASH) index was used to stratify the INTERMAP UK data into percentile groups. The DASH score from Fung et al. 3 was applied to the INTERMAP UK cohort as it uses estimated servings of seven food groups (whole grains, low fat dairy, nuts and legumes, fruits, vegetables excluding potatoes, processed meat and sugar sweetened beverages) and sodium to derive the score. To allow calculation of food group intake data, composite dishes (i.e.
dishes made from ingredients from two or more food groups, e.g. chilli con carne) were disaggregated following previous methodology 4, 5 . Gender specific quintiles of intake for each food group (g/day) and sodium (mg/day)
were calculated and points allocated to participants. Positive scoring (quintile 1 = 1 point, …, quintile 5 = 5 points)
was applied to whole grains, low fat dairy, nuts and legumes, fruits, vegetables excluding potatoes, and negative scoring (quintile 1 = 5 point, …, quintile 5 = 1 point) was applied to processed meat, sugar sweetened beverages and sodium. Higher scores signify a "healthier" diet. The quintile cut-offs are listed in Supplementary Table 3A .
To create a range for healthy eating intakes three groups were extracted from this cohort to represent unhealthy dietary intake (DASH-scores 0-10 percentile, n=67), mid-range healthy intakes (DASH scores 45-55 percentile, n=91) and healthy dietary intakes (DASH-scores (90-100 percentile, n=67). The resulting population characteristics are summarized in Supplementary Table 3B . The estimated energy expenditure 6 was calculated using a physical activity correction of 1·4 in all participants.
External validation data (2) -A healthy cohort of 66 participants from Denmark was used as validation data set
and DASH scores were calculated based on the INTERMAP U.K. quintiles. For this study, spot urine samples were collected after the first morning void to test the applicability of the model to different types of samples.
NMR spectroscopy and data pre-processing -The NMR analysis was performed at 300K on a Bruker 600MHz spectrometer using the following standard one-dimensional pulse sequence with saturation of the water resonance:
RD -gz,1 -90° -t -90° -tm -gz,2 -90° -ACQ, where RD is the relaxation delay, t is a short delay typically of about 4μs, 90° represents a 90° radio-frequency pulse, tm is the mixing time (10ms), gz,1 and gz,2 are magnetic field z-gradients both applied for 1ms, and ACQ is the data acquisition period (2·7s). Water suppression was achieved through continuous wave irradiation at the water resonance frequency using 25Hz radio-frequency pulse strength during the RD and tm. The receiver gain was set to 90·5 for all experiments. Each urine spectrum was acquired using 4 dummy scans, 32 scans, 64K time domain points and with a spectral window set to 20 ppm for urine. Prior to Fourier transformation, the free induction decays were multiplied by an exponential function corresponding to a line broadening of 0·3 Hz.
1
H NMR spectra were manually phased and digitized over the range δ -0·5 to 9·5
and imported into MATLAB (2014a, MathWorks, Natick, U.S.A. Finally, metabolites were confirmed by in situ spiking experiments using authentic chemical standards. 13 . This can give an estimate of the consistently (same mean, small variance) and similarly (same sign) contributing variables that are the most robust contributors in the model.
Supplementary
Prior to the calculation of each model the data is split into training and test (validation) sets, and the data is mean-centered within-person to account for the repeated measures design by subtracting the mean of the two spectra from the spectra of each individual, this removes between-person offsets from the data. Next, the standard deviations of the variables using the training set data are calculated, and subsequently each variable from both data sets (training and test) are divided by the standard deviation from the training data to make all variables equally important in the model (unit variance).
The external validation cohorts were centered using the mean of the training data and scaled using the a Number is related to the labels in Figure 2 . b The chemical shifts and multiplicities are listed for peaks from significantly associated metabolites. Peaks are only listed if they are in the range of the processed data (9·5-5·5 and 4·5-0·5 ppm). Multiplicity key is as follows: s -singlet, d -doublet, t -triplet, q -quartet, dddoublet of doublets, dq -doublet of quartets, 2d -two doublets, m -(other) multiplet. c 'Shift' indicates chemical shift variability of the peak, e.g. due to slight pH differences of the sample. 

Supplementary Figure 1. Study design of the metabolic profiling study.
We used the World Health Organisation's healthy eating guidelines 25 (decrease total fat (particularly saturated fat), sugar and salt consumption and increase intakes of dietary fibre, whole grain cereals, fruit and vegetables) to develop four dietary interventions ranging from low to high metabolic risk diets. Where Diet 1 is concordant with the WHO healthy guidelines and Diet 4 is least concordant with the guidelines. 19 volunteers followed four diets for 4 consecutive days in a randomized order.
Supplementary Figure 2. Predicted scores from Monte-Carlo cross-validation (MCCV) from the 24-h urine model presented in Figure 2 of the two most extreme diets (Diet 1 and 4) predicting 24-h samples from days 1, 2 and 3 of all four diets of each individual. (A)
The data presented here is from the 24-h urine collections for day 1 predicted by the model of day 3, presented in Figure 2 . The four DIs are represented by Diet 1 (•), Diet 2 (♦), Diet 3 (▲) and Diet 4 (■). To account for the repeated measures design the data (spectra) was mean-centered for each individual (see Supplementary Methods), resulting in symmetrical scores for Diets 1 and 4 for day 3. All other data are used here as validation data and thus were scaled using the mean from Diets 1 and 4 from day 3 to avoid bias. The top part of the panel gives the Kernel Density Estimate (KDE) of the predicted scores for the four diets. The bottom part shows the predicted scores (Tpred) from MCCV for each individual. 
PROTOCOL Dietary biomarker discovery using metabolomics
AIMS
To identify chemicals in urine and blood associated with recent consumption of specific foods deemed to have high public health importance (oily fish, wholegrain foods, fruits and vegetables).
DESIGN
Participants will be asked to attend the NIHR/Wellcome Trust Imperial CRF at Hammersmith Hospital for 3-days, during 4 consecutive weeks. Each week, in a randomized order, participants will receive a diet with different amounts of specific test foods:
Week 2: 50% diet Week 3: 75% diet Week 4: 100% diet POPULATION We will be studying healthy overweight men and women aged between 21 and 65 years.
ELIGIBILITY
Men and women with a body mass index of 20-35 aged between 21 to 65 years will be eligible to this study.
DURATION 4 weeks.
INTRODUCTION
Over the last 60 years, significant increases in longevity have been accompanied by a growing burden of age-related diseases including, coronary heart disease, type 2 diabetes and many cancers and a by dramatic increase in obesity prevalence. There is strong evidence that dietary choices modulate risk of these diseases and strategies for reducing chronic disease burden emphasize the importance of changing dietary patterns (1, 2). Current public health guidelines have common themes that encourage consumption of specific food groups, for example oily fish, wholegrain foods, fruits and vegetables whilst reducing intakes of fatty and sugary foods.
A key factor in effective implementation of public health strategies is the need for validated population screening methods with which to determine the effectiveness of 'healthy eating' interventions in changing dietary habits. Further improvements in population health will require the development of evidence-based interventions to enhance consumption of specific foods and food groups to lower the risk of developing specific major chronic diseases and to promote lifelong health. These aspirations are predicated on the availability of robust tools for measuring dietary exposure.
Unfortunately the commonly used dietary exposure assessment methods (e.g. Food Frequency Questionnaires or diet diaries) are difficult to validate, subject to individual bias and depend upon food composition tables for estimation of intakes of energy, nutrients and other food constituents (3) (4) (5) . Thus, it is difficult to assess if lack of effect of a healthy eating strategy is due to poor take up of the dietary advice, inadequate assessment methodology, or if the diet has no biological/health effect.
Significant advances have been made recently in developing biomarkers of dietary intake which are more objective and which are cost effective for larger studies and surveys. Use of urinary biomarkers is of particular interest as they reflect the end product of metabolism. However, chemical biomarkers are available for only a relatively small number of specific foods and food components and most are of uncertain validity (6-8).
Significant advances have been made recently in developing 'biomarkers' of dietary intake based on metabolites found in urine and blood but, currently, chemical biomarkers are available for only a relatively small number of specific foods and food components and most are of uncertain validity.
"Metabolomics" describes the measure of all (or many) of the metabolites (small molecules) in biological fluids such as blood or urine. Following digestion, absorption and metabolism, foods give rise to thousands of different metabolites in the human body and the appearance of certain metabolites is characteristic of particular foods. Volunteers will arrive at approximately 8.30am on the first morning having fasted overnight. Volunteers will be given set menus for breakfast, lunch and evening meals. Urine (18 x 40 ml) and blood samples (6 x 10 ml) will be collected each 3-day study period and subjected to metabolomics analyses to investigate:
1. The quantitative relationship between the amount of test food consumed and biomarker abundance in urine and blood. 2. The kinetics of signal decay.
PARTICIPANT ENTRY PRE-RANDOMISATION EVALUATIONS
Potential participants will first have a short telephone interview to assess their suitability for the study. Potential participants will then be interviewed and examined by one of the research doctors.
They will have blood tests and height, weight, hip and waist measurements. They will have an electrocardiogram (ECG). All women of child bearing age will have a pregnancy test. 
WITHDRAWAL CRITERIA
The safety of the study participants takes priority. Any significant adverse event (as assessed by the researchers) will halt the study and the ethics committee and sponsor will be informed as per standard protocol. All adverse events will be recorded and investigators will review each adverse event as it arises. In addition, participants will be free to withdraw at any time and are not required to give a reason.
PHARMACOVIGILANCE
Adverse Event (AE): Any untoward medical occurrence in a patient or clinical study subject.
Serious Adverse Event (SAE):
Any untoward and unexpected medical occurrence that:
 results in death  is life-threatening -refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.  requires hospitalisation, or prolongation of existing inpatients' hospitalisation.  results in persistent or significant disability or incapacity  is a congenital abnormality or birth defect Medical judgement should be exercised in deciding whether an AE is serious in other situations. Important AEs that are not immediately life threatening or do not result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above, should also be considered serious.
REPORTING PROCEDURES
Contact details for reporting SAEs
Fax 020 838 33142, attention Professor Gary Frost
Please send SAE forms to Professor Gary Frost
All adverse events should be reported. Depending on the nature of the event the reporting procedures below should be followed. Any questions concerning adverse event reporting should be directed to the Chief Investigator in the first instance.
Non-serious AEs
All such events, whether expected or not, should be recorded.
Serious AEs (SEAs)
An SAE form should be completed and faxed to the Chief Investigator within 24 h. However, relapse, death and hospitalisations for elective treatment of a pre-existing condition do not need reporting as SAEs.
All SAEs should be reported to the xxxx Research Ethics Committee where in the opinion of the Chief Investigator the event was:  'related', i.e. resulted from the administration of any of the research procedures; and  'unexpected', i.e. an event that is not listed in the protocol as an expected occurrence.
Reports of related and unexpected SAEs should be submitted within 15 days of the Chief Investigator becoming aware of the event, using the NRES SAE form.
Local investigators should report any SAEs to the sponsor and their Local Research Ethics Committee and/ or Research and Development Office.
STATISTICS AND DATA ANALYSIS
A formal power calculation is not possible as this will be the first study of its type. However, recent studies have demonstrated significant changes in metabolomics profiles in cohorts of 20 volunteers (1, 2). Allowing for a dropout rate of 33%, we intend to recruit 30 volunteers for this research.
An independent researcher (i.e. not linked to the study) will be given the task of randomisation, which will be by sealed envelopes. 
REGULATORY ISSUES ETHICS APPROVAL
This study is awaiting ethical approval from the London Brent Research Ethics Committee. The study will be conducted in accordance with the recommendations for physicians involved in research on human subjects adopted by the 18 th World Medical Assembly, Helsinki 1964 and later revisions. Amendments to the protocol should be approved by the sponsor before being sent to ethics. After ethical approval, all amendments must have Trust R&D approval before they can be implemented.
CONSENT
Consent to enter the study must be sought from each participant only after a full explanation has been given, an information leaflet offered, and time allowed for consideration. Signed participant consent should be obtained. The right of the participant to refuse to participate without giving reasons must be respected. After the participant has entered the study the clinician remains free to give alternative treatment to that specified in the protocol at any stage if he/she feels it is in the participant's best interest, but the reasons for doing so should be recorded. In such cases, the participants remain within the study for the purposes of follow-up and data analyses. All participants are free to withdraw at any time from the study without giving reasons and without prejudicing further treatment.
CONFIDENTIALITY
The Chief Investigator will preserve the confidentiality of participants in the study and is registered under the Data Protection Act.
INDEMNITY
Imperial College holds negligent harm and non-negligent harm insurance policies, which apply to this study.
SPONSOR
Imperial College London will act as the main sponsor for this study. Delegated responsibilities will be assigned to the NHS trusts taking part in this study.
FUNDING
This research project is part of a grant funded by the Medical Research Council.
Participants will be reimbursed for their time. £600 will be awarded for completion of the entire study. Participants will be paid £150 for each of the 3-day interventions that they complete.
AUDITS AND INSPECTIONS
The study may be subject to inspection and audit by Imperial College London under their remit as sponsor and other regulatory bodies to ensure adherence to GCP and the NHS Research Governance Framework for Health and Social Care (2 nd edition).
PUBLICATION POLICY
The findings of the research will be published in an open-access, peer-reviewed journal. In addition we will be collaborating with patient groups and professional groups to disseminate the findings via multiple media channels such as patient association publications, print and broadcast media.
